Lung Cancer Management Methods Expand to Encompass Multiple Treatment Perspectives
April 14th 2022New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.
Single-Agent and Combo Immunotherapy Garners Mixed Excitement in Gynecologic Cancers
September 30th 2021Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.
GI Cancer Armamentarium Gains Traction With Immunotherapy, Targeted Agents
July 7th 2021Jimmy Hwang, MD, discusses the frontline indications for checkpoint inhibitors in gastric cancer and their effect on subsequent treatment decisions, the growth of targeted therapy across gastrointestinal cancers, and expectations for future research and development.
Coleman and Brown Review Advancing Applications for PARP Inhibition in Ovarian Cancer
March 25th 2021Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.